The present invention provides novel therapeutic products which are used for treating chronic non healing wounds. The present invention is related to novel therapeutic products generated from peripheral blood mononuclear cells. The present invention also provides a process of preparing the therapeutic products, an aqueous suspension for Injection, gel and patch generated from peripheral blood cells in vitro having wound healing properties.

A dental treatment method is provided. In this method, a tooth of a patient is extracted and prepared to provide a root part. A root canal in the extracted tooth is prepared and treated. A post of an abutment is fitted into the root canal to attach the root part to the abutment. The abutment having the root part is attached to a dental implant. With the root part attached to the abutment, periodontal connective tissue maintains the jaw bone associated with the extracted tooth, without significant hard tissue loss.

The present invention provides a method for forming a connective tissue body, which enables extending the ranges of design values in terms of shape, dimension, etc., of the connective tissue body. This method comprises: a fat treatment step for removing fat contained in a connective tissue body, which is formed in an environment where a biological tissue material is present, from the interior of the connective tissue body while the connective tissue body is being set in a molding tool, and for causing the shape of the connective tissue body to follow the shape of the molding tool; and a bioinert solution treatment step for immersing the connective tissue body, together with the molding tool, in a bioinert solution while the connective tissue body is being shaped so as to follow the shape of the molding tool after the fat treatment step.

The present invention refers to a process, and to the related apparatus, for the in vitro preparation of a biomimetic tissue prostheses of the tympanic membrane from mesenchymal stem cells; such prostheses are used for repairing or reconstructing the injured tympanic membrane in patients needing it, for example as a consequence of various trauma or pathologies.

Provided in this disclosure are various composite grafts having a trabecular scaffold with voids defined in at least a portion of the scaffold and a biological component positioned in at least some of the voids of the scaffold. The grafts may have a synthetic scaffold or a bone substrate scaffold. The grafts may be osteogenic, chondrogenic, osteochondrogenic, or vulnerary in nature. Also provided are methods of using the composite grafts to treat a tissue defect in a subject. Methods of manufacturing are also provided. Synthetic scaffolds are manufactured by additive manufacturing. Agitation is used to combine the biological component with the scaffold of the graft.

A bioactive filamentary structure includes a sheath coated with a mixture of synthetic bone graft particles and a polymer solution forming a scaffold structure. In forming such a structure, synthetic bone graft particles and a polymer solution are applied around a filamentary structure. A polymer is precipitated from the polymer solution such that the synthetic bone graft particles and the polymer coat the filamentary structure and the polymer is adhered to the synthetic bone graft particles to retain the graft particles.

Provided in this disclosure are various composite grafts having a trabecular synthetic scaffold with voids defined in at least a portion of the scaffold and a biological component positioned in at least some of the voids of the scaffold. The grafts may be osteogenic, chondrogenic, osteochondrogenic, or vulnerary in nature. Also provided are methods of using the composite grafts to treat a tissue defect in a subject. Methods of manufacturing are also provided. Grafts are manufactured by additive manufacturing. Agitation may be used to combine composite grafts with additional biological component.

Methods of treating a complex wound by administering to a complex wound in the individual a therapeutically effective amount of a fetal support tissue product to treat the complex wound. Methods of treating a complex lower extremity ulcer by administering to a complex lower extremity ulcer in the individual a therapeutically effective amount of a fetal support tissue product to treat the complex lower extremity ulcer. Methods of reducing or preventing scar formation from granulation tissue by administering a fetal support tissue product to granulation tissue. Methods of repairing a spina bifida defect by administering to the defect in the individual a therapeutically effective amount of an umbilical cord product.

This invention provides optimized solid substrates for promoting cell or tissue growth or restored function and uses of same, which in some aspects address a need in populations at greater risk for osteochondral, bone or cartilage disease, or in some embodiments, in subjects for whom no effective therapeutic or surgical intervention exists, or in some embodiments, in subjects for whom recovery from and/or quality of life after therapeutic intervention is not significantly improved, or not sustained over time, or a combination thereof. In some embodiments, the optimized solid substrates for promoting cell or tissue growth or restored function and uses of same, address a need in populations with therapeutic results significantly greater than the surgical standard of care. In some embodiments, the optimized solid substrates for promoting cell or tissue growth or restored function and uses of same, address treating or repairing a large osteochondral, bone or cartilage lesion site in a subject in need thereof.

An acellular product may be derived from human placenta and may be used in various scenarios for wound healing. Because the product may be acellular, the product may be processed for storage and transportation with minimal degradation. The product may include various scaffolding such as biomaterials or human tissue, and the scaffolding may be infused with various plasmas and agents. The cell-free treatment may maintain the biological activity of many therapeutic agents found within cells and may possess multiple structural components to support cellular attachment. The structural components or scaffolds may function as a reservoir of highly diffusible chemotactic and cellular-programming factors that may be useful to treat injury and disease.